Previous studies have documented that PPARγ plays a pivotal role in reducing inflammation, and treatment with PPARγ agonists may benefit intracerebral hemorrhage patients by reducing NF‐κB activation and cytokine levels.47 Here, PPARG is linked to intracerebral hemorrhage.